Russell Investments Group Ltd. Buys 14,253 Shares of Qiagen (NYSE:QGEN)

Russell Investments Group Ltd. boosted its holdings in shares of Qiagen (NYSE:QGEN) by 2.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 540,455 shares of the company’s stock after buying an additional 14,253 shares during the quarter. Russell Investments Group Ltd.’s holdings in Qiagen were worth $24,277,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC increased its holdings in Qiagen by 20.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 23,219 shares of the company’s stock valued at $1,046,000 after buying an additional 3,953 shares during the period. Tower Research Capital LLC TRC increased its holdings in Qiagen by 9.0% during the first quarter. Tower Research Capital LLC TRC now owns 5,621 shares of the company’s stock valued at $258,000 after buying an additional 465 shares during the period. Bank of Montreal Can purchased a new position in Qiagen during the second quarter valued at approximately $15,812,000. Pitcairn Co. increased its holdings in Qiagen by 4.4% during the first quarter. Pitcairn Co. now owns 6,988 shares of the company’s stock valued at $321,000 after buying an additional 294 shares during the period. Finally, Quantinno Capital Management LP increased its holdings in Qiagen by 40.5% during the second quarter. Quantinno Capital Management LP now owns 10,608 shares of the company’s stock valued at $476,000 after buying an additional 3,060 shares during the period. 57.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

QGEN has been the topic of several analyst reports. UBS Group cut their price target on shares of Qiagen from $48.00 to $42.00 and set a “neutral” rating on the stock in a report on Thursday, November 2nd. StockNews.com initiated coverage on shares of Qiagen in a report on Thursday, October 5th. They set a “buy” rating on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Qiagen from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Tuesday, October 17th. HSBC dropped their price objective on shares of Qiagen from $64.00 to $57.00 in a report on Friday, September 29th. Finally, Robert W. Baird initiated coverage on shares of Qiagen in a report on Monday, September 11th. They set an “outperform” rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.80.

Qiagen Trading Up 1.3 %

QGEN stock opened at $39.85 on Tuesday. The company’s 50-day simple moving average is $39.18 and its 200-day simple moving average is $43.12. The company has a quick ratio of 2.98, a current ratio of 3.74 and a debt-to-equity ratio of 0.37. Qiagen has a 52-week low of $34.74 and a 52-week high of $51.18. The firm has a market cap of $9.09 billion, a P/E ratio of 27.48, a PEG ratio of 11.68 and a beta of 0.40.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, October 30th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $476.00 million for the quarter, compared to analyst estimates of $469.79 million. Qiagen had a net margin of 17.01% and a return on equity of 13.15%. Qiagen’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period last year, the company posted $0.53 EPS. As a group, equities analysts forecast that Qiagen will post 2.06 EPS for the current fiscal year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.